US Broker Ratings

PROCEPT BioRobotics (PRCT) Stock Analysis: Unpacking a 32.68% Upside Potential

For investors keen on the healthcare sector, particularly in the realm of medical devices, PROCEPT BioRobotics Corporation (NASDAQ: PRCT) presents a compelling opportunity. This San Jose-based company is making waves..

Zai Lab Limited (ZLAB) Stock Analysis: Unpacking a 77% Potential Upside in Biotech Investment

Zai Lab Limited (NASDAQ: ZLAB), a prominent player in the biotechnology sector, has been drawing significant attention from investors due to its promising pipeline and strategic alliances. As a company..

Amedisys Inc (AMED) Stock Analysis: Navigating Growth in Healthcare with a 2.51% Potential Upside

Amedisys Inc (NASDAQ: AMED), a prominent player in the healthcare sector, is making waves with its specialized services in home health, hospice, and high acuity care. With a current market..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Navigating Growth Challenges with a 16% Upside Potential

DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a prominent player in the healthcare sector specializing in medical instruments and supplies, presents an intriguing investment opportunity despite its recent financial challenges. With a..

Akero Therapeutics, Inc. (AKRO) Stock Analysis: Potential Upside of Over 53% Amid Strong Analyst Ratings

Investors eyeing the healthcare sector may find Akero Therapeutics, Inc. (NASDAQ: AKRO) a compelling opportunity, particularly given its robust analyst ratings and potential upside. With a current market cap of..

Grifols, S.A. (GRFS) Stock Analysis: Assessing Its 30% Potential Upside and Strategic Growth in Healthcare

For investors keeping a close eye on the healthcare sector, Grifols, S.A. (NASDAQ: GRFS) presents a compelling opportunity, particularly with its potential upside of 30.39% based on current analyst ratings...

Axsome Therapeutics, Inc. (AXSM) Stock Analysis: A Potential 67.87% Upside in Biotech Innovation

Axsome Therapeutics, Inc. (NASDAQ: AXSM) is capturing the attention of investors with its promising potential upside of 67.87%, poised to make waves in the biotechnology industry. As the company continues..

TG Therapeutics, Inc. (TGTX) Stock Analysis: A Promising Biotech with 17% Upside Potential

TG Therapeutics, Inc. (NASDAQ: TGTX), a prominent player in the biotechnology sector, is capturing investor attention with its innovative approach to treating B-cell mediated diseases. With a market capitalization of..

Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Potential Upside and Growth Prospects in Biotech

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stands out in the competitive biotechnology sector with its impressive growth metrics and strategic collaborations, making it a compelling consideration for investors seeking exposure to..

Soleno Therapeutics, Inc. (SLNO) Investor Outlook: Analyzing a 51% Potential Upside in the Biotech Sector

Investors with a keen eye on the biotechnology sector should take a closer look at Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company making waves with its focus on..

Verona Pharma plc (VRNA): Exploring the 15.89% Potential Upside with Strong Buy Ratings

Verona Pharma plc (NASDAQ: VRNA), a prominent player in the biotechnology sector, continues to capture investor attention with its promising portfolio aimed at treating respiratory diseases with unmet medical needs...

Telix Pharmaceuticals Limited (TLX) Stock Analysis: Exploring a 38% Potential Upside in the Biotech Space

Telix Pharmaceuticals Limited (TLX), an emerging leader in the biotechnology sector, is capturing the attention of investors with its promising portfolio of radiopharmaceuticals targeting cancer and rare diseases. Based in..

Oscar Health, Inc. (OSCR): Investor Outlook on a Stock with 40.81% Potential Upside

Oscar Health, Inc. (NYSE: OSCR), a burgeoning player in the healthcare plans sector, presents a compelling case for investors seeking growth in the healthcare technology landscape. With a market capitalization..

Alkermes plc (ALKS) Investor Outlook: A 30.46% Potential Upside in the Dynamic Healthcare Sector

Alkermes plc (NASDAQ: ALKS), a prominent player in the healthcare sector, offers a compelling investment opportunity for those looking to capitalize on the biopharmaceutical industry’s growth. Headquartered in Dublin, Ireland,..

Avidity Biosciences, Inc. (RNA) Stock Analysis: Unveiling a 115% Upside Potential

Avidity Biosciences, Inc. (NASDAQ: RNA) is attracting significant attention in the biotechnology sector, thanks to its innovative approach to RNA therapeutics and a potential upside of 115.58% based on current..

Krystal Biotech, Inc. (KRYS) Investor Outlook: Exploring a Potential 62.91% Upside

Krystal Biotech, Inc. (NASDAQ: KRYS) has emerged as a significant player in the healthcare sector, specifically within the biotechnology industry. The company’s innovative approach towards treating diseases with high unmet..

Bio-Rad Laboratories (BIO) Stock Analysis: Unpacking a 40% Potential Upside in the Medical Devices Space

Bio-Rad Laboratories, Inc. (NYSE: BIO), a stalwart in the healthcare sector, operates at the intersection of life science research and clinical diagnostics. With a market capitalization of approximately $6.21 billion,..

DaVita Inc. (DVA) Stock Analysis: Exploring a 19.57% Potential Upside in the Healthcare Sector

DaVita Inc. (NYSE: DVA), a leading player in the U.S. healthcare sector, is making headlines with its robust business model centered around providing essential kidney dialysis services. As investors eye..

Vaxcyte, Inc. (PCVX) Investor Outlook: Navigating a 287% Potential Upside in Biotech

Vaxcyte, Inc. (NASDAQ: PCVX) is generating buzz in the biotechnology sector with its innovative approach to vaccine development. With a focus on conjugate and novel protein vaccines targeting bacterial infectious..

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 36% Potential Upside Amidst Biotech Innovations

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is garnering significant attention in the biotechnology sector, particularly among investors intrigued by its potential upside of 36.01%. This Boston-based biotech firm specializes in rare..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds